Histidyl-tRNA synthetase-Fc conjugates
The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
1. A method of modulating an inflammatory response in vitro, comprising administering an effective amount of a composition as an immunomodulator in an assay, wherein the composition comprises a histidyl-tRNA synthetase (HRS) fusion polypeptide having at least one Fc region, where the polypeptide has an amino acid sequence that is at least 95% identical to SEQ ID NO:337, wherein the HRS fusion polypeptide is at least about 95% pure and less than about 5% aggregated, and wherein the composition is substantially endotoxin-free, thereby modulating the inflammatory response in vitro.
2. The method of claim 1 , wherein the assay is a migration assay, a cytokine production assay, a cell viability assay, a cell differentiation assay, or an Fc effector function assay.
3. The method of claim 2 , wherein the migration assay uses leukocytes or lymphocytes.
4. The method of claim 2 , wherein the cell viability or cell differentiation assays use B-cells, T-cells, monocytes, or natural killer (NK) cells.
5. The method of claim 1 , wherein the an inflammatory response comprises reducing the activation, differentiation, or migration of immune cells, increasing the production of anti-inflammatory cytokines, or reducing the production or activity of pro-inflammatory cytokines.
6. The method of claim 2 , wherein the Fc effector function comprises binding to a cognate Fc receptor selected from FcγRI, FcγRIIa, FcγRIIb1, FcγRIIb2, FcγRIIc, FcγRIIIa, FcγRIIIb and FcRn.
7. The method of claim 2 , wherein the Fc effector function is selected from phagocytosis, respiratory burst, cytokine stimulation, platelet aggregation, induction of microbe killing, induction of antibody-dependent cell-mediated cytotoxicity (ADCC), and degranulation.
8. The method of claim 2 , wherein the Fc effector function assay comprises cells selected from natural killer (NK) cells, macrophages, peripheral blood mononuclear cells (PBMCs), polymorphonuclear leukocytes (PMN), dendritic cells, mast cells, neutrophils, eosinophils, basophils, monocytes, Kupffer cells, epidermal Langerhans cells, and follicular dendritic cells.
9. The method of claim 1 , wherein the HRS fusion polypeptide comprises an amino acid sequence at least 97% identical to SEQ ID NO: 337.
10. The method of claim 1 , wherein the HRS fusion polypeptide comprises an amino acid sequence at least 98% identical to SEQ ID NO: 337.
11. The method of claim 1 , wherein the Fc region and the HRS polypeptide are separated by a peptide linker.
12. The method of claim 11 , wherein the peptide linker is about 1-10 amino acids, or 1-5 amino acids in length.
13. The method of claim 1 , wherein the HRS fusion polypeptide is substantially in dimeric form in a physiological solution.
14. The method of claim 1 , wherein the HRS fusion polypeptide has substantially the same secondary structure as a corresponding unmodified HRS polypeptide, as determined via UV circular dichroism analysis.
15. The method of claim 1 , wherein the HRS fusion polypeptide has a plasma or sera pharmacokinetic AUC profile at least 5-fold greater than a corresponding, unmodified HRS polypeptide when administered to a mammal.
16. The method of claim 1 , wherein the HRS fusion polypeptide has an anti-inflammatory activity in a cell-based assay.
17. A method for reducing lung inflammation associated with an autoimmune or inflammatory disease in a subject, or for treating an interstitial lung disease (ILD) in a subject, comprising administering to the subject a composition comprising a histidyl-tRNA synthetase (HRS) fusion polypeptide having at least one Fc region, where the polypeptide has an amino acid sequence that is at least 95% identical to SEQ ID NO:337, wherein the HRS fusion polypeptide is at least about 95% pure and less than about 5% aggregated, and wherein the composition is substantially endotoxin-free.
18. The method of claim 17 , wherein the autoimmune or inflammatory disease is selected from sarcoidosis, systemic scleroderma, respiratory distress syndrome including adult respiratory distress syndrome (ARDS), granulomatosis, asthma, and immune responses mediated by acute and delayed hypersensitivity.
19. The method of claim 17 , wherein the ILD is caused by connective tissue or autoimmune disease, or occupational and environmental exposure.
20. The method of claim 19 , wherein the connective tissue or autoimmune disease includes scleroderma/progressive systemic sclerosis, lupus (systemic lupus erythematosus), rheumatoid arthritis, or polymyositis/dermatomyositis.
21. The method of claim 19 , wherein the occupational and environmental exposure includes exposure to dust, gases, poisons, chemotherapy, or radiation therapy.
22. The method of claim 17 , wherein the HRS-Fc fusion polypeptide reduces immune cell activation and invasion into damaged lung.
23. The method of claim 17 , wherein the HRS fusion polypeptide comprises an amino acid sequence at least 97% identical to SEQ ID NO: 337.
24. The method of claim 17 , wherein the HRS fusion polypeptide comprises an amino acid sequence at least 98% identical to SEQ ID NO: 337.
25. The method of claim 17 , wherein the Fc region and the HRS polypeptide are separated by a peptide linker.
26. The method of claim 25 , wherein the peptide linker is about 1-10 amino acids, or 1-5 amino acids in length.
27. The method of claim 17 , wherein the HRS fusion polypeptide is substantially in dimeric form in a physiological solution.
28. The method of claim 17 , wherein the HRS fusion polypeptide has substantially the same secondary structure as a corresponding unmodified HRS polypeptide, as determined via UV circular dichroism analysis.
29. The method of claim 17 , wherein the HRS fusion polypeptide has a plasma or sera pharmacokinetic AUC profile at least 5-fold greater than a corresponding, unmodified HRS polypeptide when administered to a mammal.
30. The method of claim 20 , wherein the HRS fusion polypeptide has an anti-inflammatory activity in a cell-based assay.